Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Biostage, Inc. (BSTG : OTC)
 
 • Company Description   
Biostage, Inc. is a biotechnology company. It is engaged in developing bioengineered organ implants based on the company's new Cellframe (TM) technology to treat life-threatening conditions of the esophagus, trachea or bronchus. Biostage Inc., formerly known as Harvard Apparatus Regenerative Technology Inc., is based in HOLLISTON, Mass.

Number of Employees: 8

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.89 Daily Weekly Monthly
20 Day Moving Average: 868 shares
Shares Outstanding: 13.88 (millions)
Market Capitalization: $67.88 (millions)
Beta: -0.95
52 Week High: $9.00
52 Week Low: $4.30
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -17.82% -20.93%
12 Week -14.21% -20.36%
Year To Date -11.09% -19.13%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
84 October Hill Road Suite 11
-
Holliston,MA 01746
USA
ph: 774-233-7300
fax: 774-233-7302
jdamasio@biostage.com http://www.biostage.com
 
 • General Corporate Information   
Officers
Junli He - Chief Executive Officer; Director; and Chairman
Jason Jing Chen - Vice Chairman
Joseph Damasio Jr. - Chief Financial Officer
David Green - Director
Ting Li - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09074M202
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/03/23
Share - Related Items
Shares Outstanding: 13.88
Most Recent Split Date: 12.00 (0.05:1)
Beta: -0.95
Market Capitalization: $67.88 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -20.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/23 - -
12/31/22 - -
09/30/22 - -
ROA
03/31/23 - -174.43
12/31/22 - -157.80
09/30/22 - -281.32
Current Ratio
03/31/23 - 2.73
12/31/22 - 1.17
09/30/22 - 2.21
Quick Ratio
03/31/23 - 2.73
12/31/22 - 1.17
09/30/22 - 2.21
Operating Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Net Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Pre-Tax Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Book Value
03/31/23 - -0.08
12/31/22 - -0.26
09/30/22 - -0.16
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Capital
03/31/23 - -
12/31/22 - -
09/30/22 - -
 

Powered by Zacks Investment Research ©